Pembrolizumab and atezolizumab, targeting PD-1 and PD-L1 respectively, have been gradually incorporated into the treatment guidelines in many countries and recommended as a clinical treatment option for HCC. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.